Cytomegalovirus infection after liver transplantation: Current concepts and challenges

World Journal of Gastroenterology

Volumn 14, Issue 31, 2008, Pages 4849-4860

  Razonable, Raymund Rabe ^a  

^a Department of Health Sciences Research   (United States)

Author keywords

Cytomegalovirus; Hepatitis; Maribavir; Outcome; Prophylaxis; Transplantation; Treatment; Valganciclovir

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BENZIMIDAVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; PREDNISONE; TOLL LIKE RECEPTOR; VALGANCICLOVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; RIBONUCLEOSIDE;

AGE DISTRIBUTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; GENDER BIAS; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INNATE IMMUNITY; LIVER TRANSPLANTATION; MORTALITY; NEPHROTOXICITY; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; RISK FACTOR; VIRUS REACTIVATION; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; CYTOMEGALOVIRUS; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; PATHOGENICITY; TREATMENT OUTCOME;

ACYCLOVIR; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; GANCICLOVIR; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; RIBONUCLEOSIDES; RISK FACTORS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 55449130458     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.4849     Document Type: Editorial

References (24)

1. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes 2004; 11: 77-86
2. Razonable RR, Paya CV, Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003; 10: 60-65
3. Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR. Delayed-onset primary, cytomegalovirus disease after liver transplantation. Liver Transpl 2007, 13: 1703-1709.
4. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson C.A. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected] Lancet 1997; 350: 1729-1733
5. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620
6. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097
7. Paya CV, Hermans PE, Wiesner RH, Ludwig J, Smith TF, Rakela J, Krom RA. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis 1989; 160: 752-758
8. Razonable RR, van Cruijsen H, Brown RA, Wilson JA, Harmsen WS, Wiesner RH, Smith TF, Paya CV. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003; 187: 1801-1808
9. Singh N, Wagener MM, Strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2006; 144: 456-457; author reply 457
10. Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection? Liver Transpl 2005; 11: 700-704
11. Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005; 62: S7-S13
12. Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JF, Paya CV. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184: 1461-1464,
13. Razonable RR, Paya CV. Infections and allograft rejection - intertwined complications of organ transplantation. Swiss Med Wkly 2005; 135: 571-573
14. O'Grady JG, Alexander GJ, Sutherland S, Donaldson PT, Harvey F, Portmann B, Calne RY, Williams R. Cytomegalovirus infection and donor/ recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 1988; 2: 302-305.
15. Noack KB, Wiesner RH, Batts K, vall Hoek B, Ludwig J. Severe ductopenic rejection with features of vanishing bile duct syndrome: clinical, biochemical, and histologic evidence for spontaneous resolution. Transplant Proc 1991; 23: 1448-1451
16. Ludwig J, Wiesner RH, Batts KP, Perkins JD, Krom RA. The acute vanishing bile duct syndrome (acute irreveisible rejection) after orthotopic liver transplantation. Hepatology 1987; 7: 476-483
17. Pastacaldi S, Teixeira R, Montalto P; Kolles K, Burroughs AK. Hepatic artery thrombosis after orthotopic liver transplantation: a review of nonsurgical causes. Liver Transpil 2001; 7: 75-81
18. Madalosso C, de Souza NF Jr, Ilstrup DM, Wiesner RH, Krom RA. Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. Transplantation 1998; 66: 294-297
19. Eid AJ, Razonable RR. Cytomegalovirus diseasp in solid organ transplant recipients: advances lead to new challenges and opportunities. Current Opinion in Organ Transplantation 2007; 12: 610-617
20. Peleg AY, Husain S, Qureshi ZA, Silveira FP, Sarumi M, Shutt KA, Kwak EJ, Paterson DL. Risk factors, clinical characterislIcs, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44: 1307-1314
21. Mendez JC, Dockrell DH, Espy MJ, Smith TF, Wilson JA, Harmsen WS, Ilstrup D, Paya CV. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001; 183: 179-184
22. Dockrell DH, Prada J, Jones MF, Patel R, Badley AD, Harmsen WS, Ilstrup DM, Wiesner RH, Krom RA, Smith TF, Paya CV. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis 1997; 176: 1135-1140.
23. Mendez J, Espy M, Smith TF, Wilson J, Wiesner R, Paya CV. Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation. Transplantation 1998; 65: 1477-1481
24. Razonable RR, Rivero A, Brown RA, Hart CD, Espy MJ, van Cruijsen H, Wilson J, Groettum C, Kremers W, Smith TF, Paya CV. Detection of simultaneous betaherpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003; 17: 114-120